AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24005959 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (RT) for 12 weeks, 3 times per week (n=28)
Number of subjects: 36
Study 24005959 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 weeks of no training, n=8)
Number of subjects: 36
Study 23671022 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee 6 (6 mg caffeine/kg body weight)
Number of subjects: 33
Study 23671022 — intervention group
Group type: COMPARATOR
Intervention: Coffee 3 (3 mg caffeine/kg body weight)
Number of subjects: 33
Study 23671022 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 33
Study 19131132 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (10 microg/kg/day)
Number of subjects: 54
Study 19131132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 18199394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DA)
Number of subjects: 16
Study 18199394 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE)
Number of subjects: 16
Study 16893641 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative concurrent chemoradiotherapy (5‐fluorouracil (5‐FU) 500 mg/m2/d continuous infusion for 4 cycles and vinorelbine 25 mg/m2 on specific days)
Number of subjects: 60
Study 16893641 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative concurrent chemoradiotherapy
Number of subjects: 60
Study 14705688 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep removal of the LMA
Number of subjects: 196
Study 14705688 — intervention group
Group type: COMPARATOR
Intervention: Awake removal of the LMA
Number of subjects: 196
Study 11293237 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg i.v. monthly
Number of subjects: 46
Study 11293237 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy alone)
Number of subjects: 46
Study 8864319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 800 mg given twice daily for 28 days
Number of subjects: 27
Study 1735313 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK (oral) for over three years, mitomycin C intravenously on the day of and the day after surgery, followed by oral 5-fluorouracil (5-FU) for over six months.
Number of subjects: 448
Study 1735313 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C intravenously on the day of and the day after surgery, followed by oral 5-fluorouracil (5-FU) for over six months.
Number of subjects: 448
Study 6122188 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (7.5 mg)
Number of subjects: 40
Study 6122188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (3.0 mg)
Number of subjects: 40
Study 6122188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg)
Number of subjects: 40
Study 6122188 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 40
Study 30420479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg once daily) with artemether-lumefantrine
Number of subjects: 0
Study 30420479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg once daily) with artesunate-amodiaquine
Number of subjects: 0
Study 28971551 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised strength training (n=50)
Number of subjects: 152
Study 28971551 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised Nordic Walking (n=50)
Number of subjects: 152
Study 28971551 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised home-based exercise (n=52)
Number of subjects: 152
Study 26966119 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of DAR-0100A
Number of subjects: 49
Study 26966119 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of DAR-0100A
Number of subjects: 49
Study 26966119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 49
Study 24574549 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over left dorsolateral prefrontal cortex for 20 minutes
Number of subjects: 55
Study 24574549 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 55
Study 18758805 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet/3 days per week resistance training (WLRT)
Number of subjects: 67
Study 18758805 — intervention group
Group type: COMPARATOR
Intervention: Diet (WL)
Number of subjects: 67
Study 15251155 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-reading arm (oncologist and radiologist independently interpreting radiographs)
Number of subjects: 869
Study 15251155 — intervention group
Group type: COMPARATOR
Intervention: Single-reading arm (interpretation by an oncologist only)
Number of subjects: 869
Study 15251155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 869
Study 11722957 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess dietary cysteine (21 mg x kg(‐1) x d(‐1))
Number of subjects: 6
Study 11722957 — intervention group
Group type: COMPARATOR
Intervention: No exogenous cysteine
Number of subjects: 6
Study 9135425 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured silicone gel-filled implants
Number of subjects: 49
Study 9135425 — intervention group
Group type: COMPARATOR
Intervention: Smooth silicone gel-filled implants
Number of subjects: 49
Study 8189476 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.15 mg/kg/day, Somatropin, Genentech, Inc.)
Number of subjects: 20
Study 8189476 — intervention group
Group type: COMPARATOR
Intervention: Vehicle of infusion (Control)
Number of subjects: 20
Study 3555687 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cefotaxime
Number of subjects: 0
Study 3555687 — intervention group
Group type: COMPARATOR
Intervention: Single-dose cephradine
Number of subjects: 0
Study 11483273 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR at 12 months of age
Number of subjects: 937
Study 11483273 — intervention group
Group type: COMPARATOR
Intervention: Revaccination with MMR at 15 months of age
Number of subjects: 937
Study 11483273 — intervention group
Group type: COMPARATOR
Intervention: MV at 9 months followed by MMR at 15 months
Number of subjects: 937
Study 31297582 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids (Group T, n: 42)
Number of subjects: 124
Study 31297582 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroids (0.8 mg/kg/day peroral, Group S, n: 42)
Number of subjects: 124
Study 31297582 — intervention group
Group type: COMPARATOR
Intervention: Combined steroids (0.4 mg/kg/day peroral + topical, Group C, n: 40)
Number of subjects: 124
Study 28891198 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted medical nutrition (TMN) - 230 kcal; 2 g omega-3 fatty acids; 10 μg 25-hydroxy-vitamin D3, administered twice daily for 12 weeks.
Number of subjects: 45
Study 28891198 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric comparator, administered twice daily for 12 weeks.
Number of subjects: 45
Study 28273329 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper mode of administration
Number of subjects: 201
Study 28273329 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic mode of administration
Number of subjects: 201
Study 28273329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-mode administration
Number of subjects: 201
Study 28273329 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized self-report instruments
Number of subjects: 201
Study 25354927 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based behavioral activation intervention (Bounce Back Now); specific dosage and duration not mentioned.
Number of subjects: 2024
Study 22490629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy (double maintenance dose of clopidogrel 150 mg/d and aspirin 300 mg/d, followed by cilostazol 50-100 mg bid if HPR persists)
Number of subjects: 840
Study 22490629 — intervention group
Group type: COMPARATOR
Intervention: Standard antiplatelet therapy (aspirin 300 mg/d and clopidogrel 75 mg/d)
Number of subjects: 840
Study 22490629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antiplatelet therapy
Number of subjects: 840
Study 22490629 — intervention group
Group type: COMPARATOR
Intervention: Standard antiplatelet therapy
Number of subjects: 840
Study 19436934 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 750
Study 19436934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study 17697904 — intervention group
Group type: EXPERIMENTAL
Intervention: LID 40 mg + MET 5 mg
Number of subjects: 240
Study 17697904 — intervention group
Group type: EXPERIMENTAL
Intervention: LID 40 mg + MET 10 mg
Number of subjects: 240
Study 17697904 — intervention group
Group type: COMPARATOR
Intervention: LID 40 mg + MET 2.5 mg
Number of subjects: 240
Study 17697904 — intervention group
Group type: COMPARATOR
Intervention: LID + saline
Number of subjects: 240
Study 15716194 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible fluorescence cystoscopy (FFC) with hexaminolevulinate (HAL)
Number of subjects: 20
Study 15716194 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fluorescence cystoscopy (RFC) with hexaminolevulinate (HAL)
Number of subjects: 20
Study 15716194 — intervention group
Group type: COMPARATOR
Intervention: Rigid white light cystoscopy (RWLC)
Number of subjects: 20
Study 15716194 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall fluorescence intensity using FFC
Number of subjects: 20
Study 12229134 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 60
Study 12229134 — intervention group
Group type: COMPARATOR
Intervention: Control (no BIS monitoring)
Number of subjects: 60
Study 10081301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 9014
Study 8613305 — intervention group
Group type: EXPERIMENTAL
Intervention: GOI method (Indian modification)
Number of subjects: 5
Study 8613305 — intervention group
Group type: COMPARATOR
Intervention: WHO method
Number of subjects: 5
Study 1693007 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosine and an antiseptic (Chlorhexidine or PVP iodine)
Number of subjects: 0
Study 1693007 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine or PVP iodine alone
Number of subjects: 0
Study 1693007 — intervention group
Group type: EXPERIMENTAL
Intervention: Dakin solution after 15 days of inefficacy of previous antiseptics
Number of subjects: 0
Study 7281085 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with chemotherapy (adriamycin and 5-fluorouracil)
Number of subjects: 82
Study 7281085 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 82
Study 31446893 — intervention group
Group type: EXPERIMENTAL
Intervention: Waivered physicians (n=40)
Number of subjects: 55
Study 31446893 — intervention group
Group type: COMPARATOR
Intervention: Non-waivered physicians (n=15)
Number of subjects: 55
Study 28755866 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium brackets with fluorine protection
Number of subjects: 30
Study 28755866 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium brackets without fluorine protection
Number of subjects: 30
Study 28755866 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless-steel brackets with fluorine protection
Number of subjects: 30
Study 28755866 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless-steel brackets without fluorine protection
Number of subjects: 30
Study 25249430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-optic bronchoscope-guided intubation with lingual traction
Number of subjects: 91
Study 25249430 — intervention group
Group type: COMPARATOR
Intervention: Fiber-optic bronchoscope-guided intubation alone
Number of subjects: 91
Study 23252583 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam + Low-level laser therapy
Number of subjects: 32
Study 23252583 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 32
Study 23252583 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 32
Study 23252583 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser + Piroxicam
Number of subjects: 32
Study 23252583 — intervention group
Group type: COMPARATOR
Intervention: Laser + Placebo Piroxicam
Number of subjects: 32
Study 22233396 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine
Number of subjects: 150
Study 22233396 — intervention group
Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 150
Study 22233396 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine plus Topiramate
Number of subjects: 150
Study 19240603 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 91
Study 19240603 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 91
Study 17296530 — intervention group
Group type: EXPERIMENTAL
Intervention: Alicaforsen
Number of subjects: 331
Study 17296530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 15377583 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg kg(‐1) loading dose followed by 0.05 mg kg(‐1) min(‐1) infusion)
Number of subjects: 97
Study 15377583 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 97
Study 11427837 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 30
Study 11427837 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 30
Study 11427837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9951756 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry and capnography
Number of subjects: 113
Study 9951756 — intervention group
Group type: COMPARATOR
Intervention: No access to pulse oximetry and capnography
Number of subjects: 113
Study 8026260 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice a day plus amoxicillin 1 g twice a day (group I, N = 30)
Number of subjects: 90
Study 8026260 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice a day plus amoxicillin 1 g twice a day (group II, N = 30)
Number of subjects: 90
Study 8026260 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice a day plus amoxicillin 1 g three times a day (group III, N = 30)
Number of subjects: 90
Study 2574836 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (initial bolus 0.5 mg/kg, continuous infusion 5.5 micrograms/kg/min)
Number of subjects: 60
Study 2574836 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (initial bolus 0.08 mg/kg, continuous infusion 0.9 micrograms/kg/min)
Number of subjects: 60
Study 2574836 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium with prostigmin (0.04 mg/kg) in recovery phase
Number of subjects: 60
Study 2574836 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium with prostigmin (0.04 mg/kg) in recovery phase
Number of subjects: 60
Study 2574836 — intervention group
Group type: COMPARATOR
Intervention: Atracurium and Vecuronium (both groups)
Number of subjects: 60
Study 31996926 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration continuous renal replacement therapy
Number of subjects: 120
Study 31996926 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study 31178155 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months of adjuvant trastuzumab
Number of subjects: 3384
Study 31178155 — intervention group
Group type: COMPARATOR
Intervention: 6 months of adjuvant trastuzumab
Number of subjects: 3384
Study 28215362 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sirukumab every 4 weeks
Number of subjects: 878
Study 28215362 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sirukumab every 2 weeks
Number of subjects: 878
Study 28215362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 878
Study 25082793 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-protein diet supplemented with amino acids and ketoacids (s-VLPD)
Number of subjects: 9610
Study 25082793 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 9610
Study 25082793 — intervention group
Group type: COMPARATOR
Intervention: Tertiary nephrology care (TNC)
Number of subjects: 9610
Study 22568388 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational multimedia campaign
Number of subjects: 2014
Study 21624226 — intervention group
Group type: EXPERIMENTAL
Intervention: DTI and MRS examination in VCI group
Number of subjects: 52
Study 21624226 — intervention group
Group type: COMPARATOR
Intervention: DTI and MRS examination in control group
Number of subjects: 52
Study 18452749 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor point injection technique with 60U of BTX‐A (Botox) in 2.4mL or 30U BTX‐A in 1.2mL of saline
Number of subjects: 31
Study 18452749 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisite distributed injection technique with 90U of BTX‐A in 3.6mL
Number of subjects: 31
Study 17181386 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 0
Study 12698647 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravenous injection of Irinotekan (group 1)
Number of subjects: 47
Study 12698647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial regional injection of Irinotekan (group 2)
Number of subjects: 47
Study 12698647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial therapy with Irinotekan (group 3)
Number of subjects: 47
Study 12698647 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic intravenous therapy with Irinotekan (group 4)
Number of subjects: 47
Study 10886044 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg as simplified omeprazole suspension
Number of subjects: 12
Study 10886044 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg as simplified lansoprazole suspension
Number of subjects: 12
Study 10886044 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole capsules
Number of subjects: 12
Study 10886044 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole capsules
Number of subjects: 12
Study 9298736 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a, 9 megaunits thrice weekly for six months
Number of subjects: 29
Study 9298736 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 patients)
Number of subjects: 29
Study 8373935 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame 30 mg/kg/day
Number of subjects: 13
Study 8373935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3780838 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide 20 mg
Number of subjects: 13
Study 3780838 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg
Number of subjects: 13
Study 3780838 — intervention group
Group type: COMPARATOR
Intervention: Torasemide 20 mg and Furosemide 40 mg
Number of subjects: 13
Study 31005204 — intervention group
Group type: EXPERIMENTAL
Intervention: Xelac: concomitant boost to bulky site (45 Gy/1.8 Gy/day, 5 sessions/week to the pelvis, +10 Gy at 1 Gy twice/week to the bulky) plus concurrent capecitabine (1650 mg/mq/day)
Number of subjects: 534
Study 31005204 — intervention group
Group type: COMPARATOR
Intervention: Xelox: 45 Gy to the pelvis + 5.4 Gy/1.8 Gy/day, 5 sessions/week to the bulky site + concurrent capecitabine (1300 mg/mq/day) and oxaliplatin (130 mg/mq on days 1, 19, 38)
Number of subjects: 534
Study 28656542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline
Number of subjects: 2033
Study 26834998 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation with physiotherapy program
Number of subjects: 24
Study 26834998 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy program alone (Control)
Number of subjects: 24
Study 21784661 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 32
Study 21784661 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 32
Study 21042701 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring by treating therapists
Number of subjects: 29
Study 21042701 — intervention group
Group type: COMPARATOR
Intervention: Scoring by independent assessor
Number of subjects: 29
Study 19411675 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal catheter approach (MIN)
Number of subjects: 200
Study 19411675 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter approach (CON)
Number of subjects: 200
Study 17341220 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component programs to prevent and control childhood obesity
Number of subjects: 0
Study 12636463 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than 1 drink weekly
Number of subjects: 5888
Study 12636463 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 to 6 drinks weekly
Number of subjects: 5888
Study 12636463 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 to 13 drinks weekly
Number of subjects: 5888
Study 12636463 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 or more drinks weekly
Number of subjects: 5888
Study 12636463 — intervention group
Group type: COMPARATOR
Intervention: Abstention
Number of subjects: 5888
Study 10666187 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (0.3‐5.0 microg/kg.d) + epoetin alfa (150 IU/kg 3 times/wk)
Number of subjects: 66
Study 10666187 — intervention group
Group type: COMPARATOR
Intervention: GM‐CSF (0.3‐5.0 microg/kg.d) + placebo (3 times/wk)
Number of subjects: 66
Study 10666187 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF +/‐ epoetin alfa
Number of subjects: 66
Study 8794786 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraprenylacetone (300 mg for four weeks)
Number of subjects: 25
Study 8794786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1523076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (5 days treatment)
Number of subjects: 22
Study 1523076 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) (5 days treatment)
Number of subjects: 22
Study 1523076 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMX (in patients with TMP-SMX-resistant organisms)
Number of subjects: 22
Study 1523076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten and TMP-SMX (both treatments)
Number of subjects: 22
Study 1523076 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten and TMP-SMX
Number of subjects: 22
Study 6823418 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented formula with taurine alone
Number of subjects: 0